Herrera MT, González Y, Juárez E

Language: Spanish
References: 13
Page: 267-275
PDF size: 255.75 Kb.

ABSTRACT

Interferon-γ (IFN-γ) is one of the most important cytokines in pulmonary tuberculosis immune responses. Its main function is to activate antimicrobial mechanisms in macrophages. Patients with IFN-γ deficiencies are unable to control M. tuberculosis, thus the addition of rhIFN-γ is an alternative treatment. Objective: To evaluate the effects of recombinant human IFN-γ (rhIFN-γ) on human alveolar macrophages infected with M. tuberculosis. Methods: We infected alveolar macrophages from healthy volunteers with M. tuberculosis H37Rv and treated them with rhIFN-γ to evaluate the gene expression of antimicrobial peptide LL-37 and the IRGM protein (related to autophagy) by real time PCR (qPCR), tumoral necrosis factor-α (TNF-α) production by ELISA and intracellular growth control by colony forming units (CFU) of M. tuberculosis. Results: Uninfected macrophages over expressed IRGM after rhIFN-γ treatment, whereas infected macrophages over expressed LL-37. However, the addition of rhIFN-γ did not have a significant effect on production TNF-α production and intracellular growth control of M. tuberculosis. Conclusion: Although LL-37 expression was induced, it was not associated with the killing of M. tuberculosis, suggesting that there are IFN-γ-independent mechanisms involved in the pathogen elimination.

REFERENCES

1. WHO. Global Tuberculosis Report 2017. World Health Organization 2017. WHO/HTM/TB/2017.23

2. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392(10150):821-834. doi: 10.1016/S0140- 6736(18)31644-1.

3. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367(16):1508-1518. doi: 10.1056/ NEJMoa1201964.

4. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drugresistant tuberculosis. J Thorac Dis 2015;7(4):603-615. doi: 10.3978/j.issn.2072-1439.2015.03.10.

5. Migliori GB, Eker B, Richardson MD, et al.; TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009;34(2):387-393. doi: 10.1183/09031936.00009509.

6. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. WHO/HTM/TB/2016.04. ISBN 978 92 4 154963 9.

7. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrugresistant (MDR) and extensively drugresistant (XDR) tuberculosis: a systematic review and metaanalysis. Ann Clin Microbiol Antimicrob 2016;15(1):41. doi: 10.1186/s12941-016-0156-y.

8. ht tp: //www.stoptb.org/gdf/drugsupply/pc3. asp?PID=1069

9. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;45(1):161-170. doi: 10.1183/09031936.00035114.

10. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40(6):1430-1442. doi: 10.1183/09031936.00022912.

11. Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther 2016;14(10):901-915. doi: 10.1080/14787210.2016.1225498.

12. Laniado-Laborín R. Adverse effects and toxicity of antituberculosis drugs. In: Laniado-Laborín R, editor. Drug Resistant Tuberculosis-Practical Guide for Clinical Management. United Arab Emirates: Bentham Publishers; 2015. p. 78-79.

13. Zareifopoulos N, Panayiotakopoulos G. Neuropsychiatric effects of antimicrobial agents. Clin Drug Investig 2017;37(5):423-437. doi: 10.1007/s40261-017-0498-z.